Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Justin Faden, Ryan Serdenes & Leslie Citrome. (2022) Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?. Expert Review of Neurotherapeutics 22:5, pages 365-376.
Read now
Read now
Amir M Meftah, Elizabeth Deckler, Leslie Citrome & Joshua T Kantrowitz. (2020) New discoveries for an old drug: a review of recent olanzapine research. Postgraduate Medicine 132:1, pages 80-90.
Read now
Read now
Leslie Citrome, Joseph P McEvoy, Mark S Todtenkopf, David McDonnell & Peter J Weiden. (2019) A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future. Neuropsychiatric Disease and Treatment 15, pages 2559-2569.
Read now
Read now
Justin Faden & Leslie Citrome. (2019) Resistance is not futile: treatment-refractory schizophrenia – overview, evaluation and treatment. Expert Opinion on Pharmacotherapy 20:1, pages 11-24.
Read now
Read now
Andy R. Eugene & Jolanta Masiak. (2017) A pharmacodynamic modelling and simulation study identifying gender differences of daily olanzapine dose and dopamine D2-receptor occupancy. Nordic Journal of Psychiatry 71:6, pages 417-424.
Read now
Read now
Leslie Citrome. (2009) Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection. Patient Preference and Adherence 3, pages 345-355.
Read now
Read now
Articles from other publishers (21)
Heidi TaipaleAntti TanskanenJari Tiihonen. (2023) Safety of Antipsychotic Polypharmacy Versus Monotherapy in a Nationwide Cohort of 61,889 Patients With Schizophrenia. American Journal of Psychiatry 180:5, pages 377-385.
Crossref
Crossref
Octavian Vasiliu. (2023) Opţiuni terapeutice în schizofrenia ultrarezistentă. Intervenţii farmacologice (I). Psihiatru.ro 72:1, pages 28.
Crossref
Crossref
Louisa Gannon, John Reynolds, Martin Mahon, Fiona Gaughran & John Lally. (2023) High-dose olanzapine in treatment-resistant schizophrenia: a systematic review. Therapeutic Advances in Psychopharmacology 13, pages 204512532311687.
Crossref
Crossref
Tyler J. Torrico. (2022) The pathophysiology of rapid fluctuations in mental status associated with olanzapine: A case report. Frontiers in Psychiatry 13.
Crossref
Crossref
Joshua Gerving, Heather Walser & Anne C. Kelly. (2022) Postinjection delirium/sedation syndrome in a transgender man undergoing hormone therapy. Mental Health Clinician 12:4, pages 263-266.
Crossref
Crossref
Guangcai Yu, Siqi Cui, Tianzi Jian, Cece Sun, Longke Shi, Yaqian Li, Baotian Kan & Xiangdong Jian. (2021) Gluteal muscle damage and rhabdomyolysis after olanzapine poisoning: a case report. Journal of International Medical Research 49:10, pages 030006052110477.
Crossref
Crossref
Leslie Citrome & Jan Volavka. (2021) Specific Anti-hostility Effects of Atypical Antipsychotics in Persons with Schizophrenia: From Clozapine to Cariprazine. Harvard Review of Psychiatry 29:1, pages 20-34.
Crossref
Crossref
Zehra Boz, Minmin Hu, Yinghua Yu & Xu-Feng Huang. (2020) N-acetylcysteine prevents olanzapine-induced oxidative stress in mHypoA-59 hypothalamic neurons. Scientific Reports 10:1.
Crossref
Crossref
Thomas RE Barnes, Richard Drake, Carol Paton, Stephen J Cooper, Bill Deakin, I Nicol Ferrier, Catherine J Gregory, Peter M Haddad, Oliver D Howes, Ian Jones, Eileen M Joyce, Shôn Lewis, Anne Lingford-Hughes, James H MacCabe, David Cunningham Owens, Maxine X Patel, Julia MA Sinclair, James M Stone, Peter S Talbot, Rachel Upthegrove, Angelika Wieck & Alison R Yung. (2019) Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 34:1, pages 3-78.
Crossref
Crossref
David Cunningham Owens. (2018) Tardive dyskinesia update: treatment and management. BJPsych Advances 25:2, pages 78-89.
Crossref
Crossref
Joseph Westermeyer. (2019) Call for “High-Dose” Olanzapine Research in Treatment-Resistant Psychosis. Journal of Nervous & Mental Disease 207:1, pages 45-47.
Crossref
Crossref
Marina Šagud, Bjanka Vuksan-Ćusa, Nada Božina, Mila Lovrić, Alma Mihaljević-Peleš & Milivoj Kramarić. (2016) Olanzapine Long-Acting Injections After Neuroleptic Malignant Syndrome. Journal of Clinical Psychopharmacology 36:6, pages 733-735.
Crossref
Crossref
Ali Almuqdadi, Nailya Bulatova & Al-Motassem Yousef. (2016) The effect of atypical antipsychotics on platelet aggregation. Open Journal of Hematology 7, pages 1.
Crossref
Crossref
Takefumi Suzuki, Hiroyuki Uchida, Hiroyoshi Takeuchi, Kenichi Tsunoda, Tomomi Ishizuki & Masaru Mimura. (2015) Optimization of psychopharmacotherapy for schizophrenia in a male, locked, non-acute unit serving for persistently ill patients over one year. Psychiatry Research 228:1, pages 26-30.
Crossref
Crossref
Seiya Miyamoto, David B. Merrill, L. Fredrik Jarskog, W. Wolfgang Fleishhacker, Stephen R. Marder & Jeffrey A. Lieberman. 2015. Psychiatry. Psychiatry
2088
2128
.
Amirhossein Modabbernia, Parvaneh Heidari, Robabeh Soleimani, Abdolrasoul Sobhani, Zahra Atrkar Roshan, Shervin Taslimi, Mandana Ashrafi & Mohammad Jafar Modabbernia. (2014) Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: Randomized double-blind placebo-controlled study. Journal of Psychiatric Research 53, pages 133-140.
Crossref
Crossref
Marina Salviato Balbão, Jaime Eduardo Cecílio Hallak, Emerson Arcoverde Nunes, Mauricio Homem de Mello, Andresa de Toledo Triffoni-Melo, Flavia Isaura de Santi Ferreira, Cristiano Chaves, Ana Maria Sertori Durão, Adriana Pelegrino Pinho Ramos, José Alexandre de Souza Crippa & Regina Helena Costa Queiroz. (2013) Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up. Therapeutic Advances in Psychopharmacology 4:1, pages 30-36.
Crossref
Crossref
Leslie CitromeLeslie Citrome. 2013. Handbook of Treatment-resistant Schizophrenia. Handbook of Treatment-resistant Schizophrenia
29
33
.
Thomas RE Barnes. (2011) Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 25:5, pages 567-620.
Crossref
Crossref
Thomas L. Schwartz & Stephen M. Stahl. (2011) Treatment Strategies for Dosing the Second Generation Antipsychotics. CNS Neuroscience & Therapeutics 17:2, pages 110-117.
Crossref
Crossref
Priya SubramanianAbraham Rudnick. (2010) Risperidone for Individuals with Refractory Schizophrenia. Clinical Medicine Insights: Therapeutics 2, pages CMT.S3567.
Crossref
Crossref